“Securing this critical funding from CIRM is a major step forward, accelerating our path to a Phase 1 clinical trial,” said Dr. Allyson Berent, chief development officer at TransformaTx Biotherapeutics and chief science officer of FAST. “This achievement is a testament to the dedication of our incredible scientific team and the AS community, whose support has driven this program from the start.” Read the press release: https://buff.ly/4aG3NLU
关于我们
Biotechnology company focused on the development of therapies for Angelman syndrome.
- 网站
-
https://www.as2bio.com/
AS2 Bio Inc的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Middleton，MA
- 类型
- 私人持股
- 创立
- 2024
地点
-
主要
获取路线
35 Village Rd
Suite 100
US，MA，Middleton，01949